Jeremy Richards
Contributor since: 2008
Latest Articles
FDA Approval Practically A Done Deal For Keryx And AEterna Zentaris
Analysts Are Bullish On Capstone Turbine; Energized For Extreme Upside
Vical: 2012 Should Be A Huge Year
Why A123 Systems Is A Buy And Offers 700% Upside Potential Over The Next 3 Years
Arena Pharmaceuticals Has Over A 300% Upside Potential In 2012
Expecting Rentech To Double In 2012: Good Time To Buy
Geron Is Now A Bargain Buy
AEterna Zentaris And Keryx: Phase 3 Set For Success; Takeover Likely
Synthesis Energy Systems: Fueling For A Run
Interview With Dr. Frederick Wurlitzer: Bet On FDA Approval For Keryx, AEterna-Zentaris; Potential For Huge Upside
Is Roche About To Buy AEterna-Zentaris?
AEterna-Zentaris And Keryx: 2 Imminent Takeover Targets
Keryx And Aeterna Zentaris: 2 Great Buys With Good Odds On FDA Approval
AEterna Zentaris Is A Greatly Undervalued, Must-Buy Biotech
Rexahn Is a Bargain Buy
AEterna Zentaris Looks Ready to Make New Highs
Novavax Has Over 400% Upside Potential
Rentech: Increased Forecast, Upcoming Conferences Present Buying Opportunity
Extreme Networks: Trademarks of a Takeover Target
AEterna Zentaris Offers Extreme Upside Reward
Vical Is Deeply Undervalued: Technology and Pipeline Offer Upside Reward
Level 3 Offers More Upside Reward Than Downside Risk
Level 3: A Takeover Target With 100% Upside
Extreme Networks: Extreme Upside Potential
Why AEterna Zentaris Still Retains 200% to 300% Upside Potential
Buying Rentech on Upside Earnings Potential
China Precision Steel: Ready for a Major Run
Rexahn Pharma Is Considerably Undervalued Based on Prospects, Recent Developments
Betting on Valence Technology: Huge Upside Reward
Zalicus Offers Excellent Upside
Analysts Say AEterna Zentaris Should Be Valued 200% to 300% Higher
FuelCell Energy May Offer Huge Upside Reward